Marker Therapeutics, Inc.

Category: Featured

Marker Therapeutics Appoints Nadia Agopyan, Ph.D., RAC as Vice President of Regulatory Affairs

Marker Therapeutics today announced the appointment of Nadia Agopyan, Ph.D., RAC as Vice President of Regulatory Affairs, effective August 15.
Read More

Marker Therapeutics Reports Second Quarter 2019 Operating and Financial Results

Marker Therapeutics today provided a corporate update and reported financial results for the second quarter ended June 30, 2019.
Read More

Marker Therapeutics Appoints Steve Elms to its Board of Directors

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced the appointment of Steve Elms, to its Board of Directors, effective August 6.
Read More

Marker Therapeutics Reports Interim Results of its MultiTAA T Cell Therapy in Patients with Pancreatic Adenocarcinoma at AACR

Marker today announced interim data from an ongoing investigator-sponsored clinical trial led by Baylor College of Medicine, evaluating the Company’s MultiTAA T cell therapy in patients with pancreatic adenocarcinoma. The data were reviewed today in an oral presentation during a plenary session, as well as a poster presentation, at the American Association for Cancer Research’s (AACR) Immune Cell Therapies for Cancer: Successes and Challenges of CAR T Cells and Other Forms of Adoptive Therapy conference held in San Francisco, California from July 19-22, 2019.
Read More

Marker Therapeutics to Host Conference Call and Webcast to Review Interim Results from Phase 1/2 Clinical Trial with its MultiTAA T Cell Therapy in Patients with Pancreatic Adenocarcinoma

Marker Therapeutics announced it will host a conference call and webcast with a question-and-answer session on Monday, July 22, 2019 at 5:30 a.m. PDT/ 8:30 a.m. EDT to review data from an investigator-sponsored Phase 1/2 clinical trial with its MultiTAA therapy in patients with pancreatic adenocarcinoma.
Read More

Marker Therapeutics to Report Updated Results from Phase 1/2 Trial with MultiTAA Therapy in Patients with Pancreatic Adenocarcinoma

Marker Therapeutics today announced that updated clinical data from an investigator-sponsored Phase 1/2 trial led by Baylor College of Medicine were selected for oral presentation during a plenary session at the upcoming American Association for Cancer Research’s (AACR) Immune Cell Therapies for Cancer: Successes and Challenges of CAR T Cells and Other Forms of Adoptive Therapy conference.
Read More

Marker Therapeutics to Present at Two Upcoming Investor Conferences

Marker Therapeutics will present at and participate in two upcoming investor conferences.
Read More


Marker Therapeutics to Present at the Bank of America Merrill Lynch Health Care Conference

President and Chief Executive Officer, Peter L. Hoang, to present at the 2019 Bank of America Merrill Lynch Health Care Conference.
Read More

Marker Therapeutics Provides Business and Clinical Update

Company to host business update call and webcast today at 5:00 p.m. EDT
Read More